Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOLVAPTAN

All products: not a benefit

Jinarc · DIN 02437538 · 90mg & 30mg · 14-Tabs Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jinarc · DIN 02437538 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2025-07-31 Health Canada: Marketed since 2015-06-01 · brand JINARC · ATC C03XA01 TOLVAPTAN · form Tablet · route Oral · ingredients TOLVAPTAN 90 MG, TOLVAPTAN 30 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Jinarc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92186 · Verify on the e-Formulary ↗ (DIN 02437538)

Source record
DIN 02437538: Jinarc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 402800061; group id 568; item number 1518; lccId None; manufacturer id OTS Source form: 14-Tabs Pk; strength: 90mg & 30mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437538 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92186
Interchangeable products
Lupin-Tolvaptan · DIN 02557215 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications JINARC (tolvaptan) is indicated: • To slow the progression of kidney enlargement and kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). In ADPKD, kidney enlargement reflects renal cyst burden. In order to select patients who might best benefit from the effects of JINARC, clinical trials evaluated ADPKD patients having a total kidney volume (TKV) ≥ 750 mL, and/or renal function corresponding to a CKD-EPI eGFR ≥25 mL/min/1.73m2, at the time of initiation of treatment. JINARC treatment should be initiated and monitored under the supervision of a nephrologist or specialist physician with expertise in the management of patients with ADPKD and a full understanding of the benefits and risks of tolvaptan therapy including hepatic toxicity and monitoring requirements. Careful consideration and discussion of the appropriateness of JINARC treatment should be undertaken between the prescriber and patient before initiation of therapy, taking into account the potential benefits and risks of treatment. Upon mutual agreement to undertake treatment with JINARC, a signed, duly-documented, manufacturer and product-specific patient-p… https://pdf.hres.ca/dpd_pm/00085722.PDF PM date: 2026-08-12 Source product: JINARC; DIN 02437503; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Jinarc: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026